Payors Weigh in on Interface of Personalized Medicine and Comparative Effectiveness Research
December 08, 2010
Payors Weigh in on Interface of Personalized Medicine and Comparative Effectiveness Research
While payors speaking at a recent conference seemed to be of the opinion that personalized medicine lacks the evidentiary support to justify broad coverage, they suggested that CER may be a way to gather the necessary data on whether to reimburse for genomically guided medicines.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Aurora to Use Oracle's Informatics Muscle to Run More Efficient Clinical Trials; PGx in Long View
February 9, 2011 / Pharmacogenomics Reporter - UnitedHealthcare Sees Need for National Registry to Track Use, Set Coverage of Molecular Tests
November 7, 2012 / Pharmacogenomics Reporter - Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx?
March 7, 2012 / Pharmacogenomics Reporter - CMS Stance on Reimbursement of Multi-Analyte Algorithm Assays Raises Industry Concerns
September 19, 2012 / Pharmacogenomics Reporter - PMC Urges Stakeholders to Provide Feedback as PCORI Opens Comment Period for Methodology Report
July 25, 2012 / Pharmacogenomics Reporter